WallStreetZenWallStreetZen

NASDAQ: LYEL
Lyell Immunopharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for LYEL

Based on 2 analysts offering 12 month price targets for Lyell Immunopharma Inc

Min Forecast
$10.00-39.72%
Avg Forecast
$15.00-9.58%
Max Forecast
$20.00+20.55%

Should I buy or sell LYEL stock?

Based on 2 analysts offering ratings for Lyell Immunopharma Inc.

Buy
Strong Buy
1 analysts 50%
Buy
0 analysts 0%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although LYEL's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates LYEL as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their LYEL stock forecasts and price targets.

LYEL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-26
lockedlocked$00.00+00.00%2025-06-24

1 of 1

Forecast return on equity

Is LYEL forecast to generate an efficient return?

Company
N/A
Industry
257.22%
Market
146.17%

Forecast return on assets

Is LYEL forecast to generate an efficient return on assets?

Company
N/A
Industry
109.18%

LYEL earnings per share forecast

What is LYEL's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$11.71
Avg 2 year Forecast
-$11.22
Avg 3 year Forecast
-$9.36

LYEL revenue forecast

What is LYEL's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$10.7k-79.79%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$3.8M+7,116.98%
LYEL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LYEL revenue growth forecast

How is LYEL forecast to perform vs Biotechnology companies and vs the US market?

Company
281.37%
Industry
108.19%
Market
25.27%
LYEL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LYEL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LYEL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LYEL$16.59$15.00-9.58%Buy
VNDA$5.41$16.50+204.99%Strong Buy
CAPR$6.92$23.00+232.37%Strong Buy
GALT$5.11$6.00+17.42%Buy
KYTX$7.17$17.33+141.74%Strong Buy
View Top Biotech Stocks

Lyell Immunopharma Stock Forecast FAQ

Is Lyell Immunopharma Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: LYEL) stock is to Buy LYEL stock.

Out of 2 analysts, 1 (50%) are recommending LYEL as a Strong Buy, 0 (0%) are recommending LYEL as a Buy, 1 (50%) are recommending LYEL as a Hold, 0 (0%) are recommending LYEL as a Sell, and 0 (0%) are recommending LYEL as a Strong Sell.

If you're new to stock investing, here's how to buy Lyell Immunopharma stock.

What is LYEL's earnings growth forecast for 2025-2027?

(NASDAQ: LYEL) Lyell Immunopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 26.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.98%.

Lyell Immunopharma's earnings in 2025 is -$331,397,000.On average, 6 Wall Street analysts forecast LYEL's earnings for 2025 to be -$224,890,173, with the lowest LYEL earnings forecast at -$232,324,908, and the highest LYEL earnings forecast at -$213,820,678. On average, 6 Wall Street analysts forecast LYEL's earnings for 2026 to be -$215,549,686, with the lowest LYEL earnings forecast at -$263,012,882, and the highest LYEL earnings forecast at -$155,726,003.

In 2027, LYEL is forecast to generate -$179,886,011 in earnings, with the lowest earnings forecast at -$209,920,804 and the highest earnings forecast at -$145,438,405.

What is LYEL's revenue growth forecast for 2025-2027?

(NASDAQ: LYEL) Lyell Immunopharma's forecast annual revenue growth rate of 281.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.19%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.27%.

Lyell Immunopharma's revenue in 2025 is $53,000.On average, 6 Wall Street analysts forecast LYEL's revenue for 2025 to be $205,752, with the lowest LYEL revenue forecast at $0, and the highest LYEL revenue forecast at $403,435. On average, 6 Wall Street analysts forecast LYEL's revenue for 2026 to be $0, with the lowest LYEL revenue forecast at $0, and the highest LYEL revenue forecast at $0.

In 2027, LYEL is forecast to generate $73,482,848 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $151,288,216.

What is LYEL's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: LYEL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 109.18%.

What is LYEL's Price Target?

According to 2 Wall Street analysts that have issued a 1 year LYEL price target, the average LYEL price target is $15.00, with the highest LYEL stock price forecast at $20.00 and the lowest LYEL stock price forecast at $10.00.

On average, Wall Street analysts predict that Lyell Immunopharma's share price could fall to $15.00 by Sep 26, 2026. The average Lyell Immunopharma stock price prediction forecasts a potential downside of 9.58% from the current LYEL share price of $16.59.

What is LYEL's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: LYEL) Lyell Immunopharma's current Earnings Per Share (EPS) is -$24.29. On average, analysts forecast that LYEL's EPS will be -$11.71 for 2025, with the lowest EPS forecast at -$12.09, and the highest EPS forecast at -$11.13. On average, analysts forecast that LYEL's EPS will be -$11.22 for 2026, with the lowest EPS forecast at -$13.69, and the highest EPS forecast at -$8.11. In 2027, LYEL's EPS is forecast to hit -$9.36 (min: -$10.93, max: -$7.57).

What is LYEL's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: LYEL) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.